Stock comparison
Merck & Co., Inc. is 299.3x more valuable than UroGen Pharma Ltd. by market capitalization ($360.96 B vs $1.21 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 299.3x more valuable than UroGen Pharma Ltd. by market capitalization ($360.96 B vs $1.21 B).
Market value leader
MRK
Merck & Co., Inc. is 299.3x more valuable than UroGen Pharma Ltd. by market capitalization ($360.96 B vs $1.21 B).
Revenue leader
MRK
URGN: $109.79M vs MRK: $65.01B.
Profit leader
MRK
URGN: -$153.49M vs MRK: $18.25B.
Margin leader
MRK
URGN: -139.8% vs MRK: 28.1% net margin.
| Metric | URGN | MRK |
|---|---|---|
| Market cap | $1.21 B | $360.96 B |
| US-listed rank | #2444 | #30 |
| Revenue (latest FY) | $109.79M | $65.01B |
| Net income (latest FY) | -$153.49M | $18.25B |
| Net margin | -139.8% | 28.1% |
| P/E (trailing FY) | - | 19.8x |
| SEC filings | 545 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 299.3x more valuable than UroGen Pharma Ltd. by market capitalization ($360.96 B vs $1.21 B).
In their latest fiscal years, UroGen Pharma Ltd. reported $109.79M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: UroGen Pharma Ltd. and Merck & Co., Inc., or browse the full rankings.